Head-to-Head Preclinical Studies of SFA-002 as a Novel Psoriasis Treatment Presented at the 2025 American Academy of Dermatology Annual Meeting
SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oral small-molecule biosynthetic ...
Morningstar6d
Head-to-Head Preclinical Studies of SFA-002 as a Novel Psoriasis Treatment Presented at the 2025 American Academy of Dermatology Annual Meeting
Treatment with SFA-002 also showed a positive trend in reduction of Transepidermal Water Loss (TEWL), a typical phenomenon of psoriatic skin lesions. A poster entitled, "Effectiveness of SFA-002 ...